MA40318A - Procédés de transduction et de traitement de cellules - Google Patents
Procédés de transduction et de traitement de cellulesInfo
- Publication number
- MA40318A MA40318A MA040318A MA40318A MA40318A MA 40318 A MA40318 A MA 40318A MA 040318 A MA040318 A MA 040318A MA 40318 A MA40318 A MA 40318A MA 40318 A MA40318 A MA 40318A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- treatment
- chamber
- transduction
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 230000026683 transduction Effects 0.000 title abstract 3
- 238000010361 transduction Methods 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 1
- 238000011467 adoptive cell therapy Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B7/00—Elements of centrifuges
- B04B7/08—Rotary bowls
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
Abstract
L'invention porte sur des procédés, des systèmes et des kits pour le traitement cellulaire, par exemple pour un usage thérapeutique, par exemple pour une thérapie cellulaire adoptive. Les procédés fournis comprennent des procédés de transduction dans lesquels des cellules et des virus sont incubés dans des conditions qui entraînent la transduction des cellules avec un vecteur viral. L'incubation dans certains modes de réalisation est réalisée dans une cavité interne d'une chambre centrifuge généralement rigide, telle qu'une chambre cylindrique en plastique dur dont la cavité peut avoir un volume variable. Les procédés comprennent d'autres étapes de traitement, y compris celles réalisées dans une telle chambre, y compris le lavage, la sélection, l'isolement, la culture et la formulation. En particulier, la description concerne un procédé fournissant des avantages par rapport aux procédés de traitement disponibles, tels que les procédés disponibles pour un traitement à grande échelle. De tels avantages comprennent, par exemple, un coût réduit, une rationalisation, une efficacité accrue, une sécurité accrue et une reproductibilité accrue entre différents sujets et conditions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075801P | 2014-11-05 | 2014-11-05 | |
| US201562129023P | 2015-03-05 | 2015-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40318A true MA40318A (fr) | 2017-09-13 |
Family
ID=54754736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040318A MA40318A (fr) | 2014-11-05 | 2015-11-04 | Procédés de transduction et de traitement de cellules |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10428351B2 (fr) |
| EP (3) | EP4407036A3 (fr) |
| JP (3) | JP6740234B2 (fr) |
| KR (2) | KR102635942B1 (fr) |
| CN (2) | CN107109438B (fr) |
| AU (3) | AU2015343121B2 (fr) |
| BR (2) | BR112017009220B1 (fr) |
| CA (1) | CA2966538A1 (fr) |
| CY (1) | CY1123254T1 (fr) |
| DK (2) | DK3215601T3 (fr) |
| ES (1) | ES2805674T3 (fr) |
| FI (1) | FI3757206T3 (fr) |
| HR (1) | HRP20201128T1 (fr) |
| HU (1) | HUE050264T2 (fr) |
| IL (2) | IL292450A (fr) |
| LT (1) | LT3215601T (fr) |
| MA (1) | MA40318A (fr) |
| MX (3) | MX2017005823A (fr) |
| MY (1) | MY186199A (fr) |
| NZ (2) | NZ769598A (fr) |
| PH (1) | PH12017500824A1 (fr) |
| PL (2) | PL3215601T3 (fr) |
| PT (2) | PT3757206T (fr) |
| RS (1) | RS60685B1 (fr) |
| SG (2) | SG10202002324SA (fr) |
| SI (1) | SI3215601T1 (fr) |
| TW (3) | TWI787903B (fr) |
| WO (1) | WO2016073602A2 (fr) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| SG11201703203RA (en) | 2014-10-20 | 2017-05-30 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| PT3757206T (pt) | 2014-11-05 | 2024-05-21 | Juno Therapeutics Inc | Métodos de transdução e processamento de células |
| EP3533876B1 (fr) * | 2014-12-19 | 2024-05-22 | Biosafe S.A. | Traitement séquentiel de fluides biologiques |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| CA2986254A1 (fr) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions et methodes de reprogrammation de tcr au moyen de proteines de fusion |
| RU2761555C2 (ru) | 2015-10-22 | 2021-12-09 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
| WO2017153974A1 (fr) * | 2016-03-07 | 2017-09-14 | Caladrius Biosciences, Inc. | Système fermé pour le marquage et la sélection de cellules vivantes |
| EP3430549A1 (fr) | 2016-03-16 | 2019-01-23 | Juno Therapeutics, Inc. | Procédés de conception adaptative d'un régime de traitement et traitements associés |
| MA45784A (fr) | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps |
| WO2018026953A1 (fr) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions et méthodes de reprogrammation de tcr en utilisant des protéines de fusion |
| WO2018049420A1 (fr) | 2016-09-12 | 2018-03-15 | Juno Therapeutics, Inc. | Ensembles de poches de bioréacteur de perfusion |
| KR20190058509A (ko) | 2016-10-07 | 2019-05-29 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 t-세포 수용체 리프로그래밍을 위한 조성물 및 방법 |
| CA3044593A1 (fr) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions et methodes de reprogrammation de tcr au moyen de proteines de fusion |
| US20200095547A1 (en) * | 2016-12-02 | 2020-03-26 | Darya ALIZADEH | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| JP2019536461A (ja) * | 2016-12-05 | 2019-12-19 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法のための操作細胞の産生 |
| JP7228522B2 (ja) | 2017-02-27 | 2023-02-24 | ジュノー セラピューティクス インコーポレイテッド | 細胞療法における投薬に関する組成物、製造物品、および方法 |
| EA201992155A1 (ru) | 2017-03-14 | 2020-03-16 | Джуно Терапьютикс, Инк. | Способы криогенного хранения |
| EP3427052A4 (fr) * | 2017-03-27 | 2019-12-04 | Hitachi Chemical Advanced Therapeutics Solutions, LLC | Système fermé pour le marquage et la sélection de cellules vivantes |
| AU2018245749A1 (en) | 2017-03-27 | 2019-10-03 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| EP3600356A4 (fr) | 2017-03-27 | 2020-12-23 | National University of Singapore | Récepteurs chimériques de nkg2d tronqués et leurs utilisations dans une immunothérapie de cellules tueuses naturelles |
| BR112019025403A2 (pt) * | 2017-06-02 | 2020-08-18 | Juno Therapeutics Inc | artigos de fabricação e métodos para tratamento usando terapia celular adotiva |
| WO2019027850A1 (fr) | 2017-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Réactifs d'expansion de cellules exprimant des récepteurs recombinants |
| CA3185343A1 (fr) * | 2017-09-01 | 2019-03-07 | Lonza Walkersville, Inc. | Automatisation de therapie cellulaire de bout en bout |
| US20200292526A1 (en) | 2017-09-07 | 2020-09-17 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| CN111542596A (zh) | 2017-11-01 | 2020-08-14 | 朱诺治疗学股份有限公司 | 产生工程化细胞的治疗性组合物的方法 |
| MX2020004239A (es) | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Proceso para producir una composicion de celulas t. |
| JP2021502094A (ja) | 2017-11-10 | 2021-01-28 | ジュノー セラピューティクス インコーポレイテッド | 閉鎖系極低温容器 |
| MX2020005907A (es) | 2017-12-08 | 2020-10-19 | Juno Therapeutics Inc | Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma. |
| SG11202005217VA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Phenotypic markers for cell therapy and related methods |
| JP2021505168A (ja) | 2017-12-08 | 2021-02-18 | ジュノー セラピューティクス インコーポレイテッド | 操作されたｔ細胞の組成物を製造するための方法 |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| AU2019318560A1 (en) | 2018-08-09 | 2021-02-25 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| SG11202101130VA (en) | 2018-08-09 | 2021-03-30 | Juno Therapeutics Inc | Methods for assessing integrated nucleic acids |
| BR112021004261A2 (pt) | 2018-09-11 | 2021-05-25 | Juno Therapeutics Inc | métodos para análise por espectrometria de massas de composições de células geneticamente modificadas |
| SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| AU2019372331A1 (en) | 2018-11-01 | 2021-05-27 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| JP2022008735A (ja) * | 2018-11-06 | 2022-01-14 | テルモ株式会社 | 細胞製造システム、細胞製造方法、医療装置及び医療デバイス |
| EP3877054B1 (fr) | 2018-11-06 | 2023-11-01 | Juno Therapeutics, Inc. | Procédé de production de cellules t génétiquement modifiées |
| US20220008465A1 (en) | 2018-11-16 | 2022-01-13 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| BR112021010120A2 (pt) | 2018-11-30 | 2021-08-31 | Juno Therapeutics, Inc. | Métodos para dosagem e tratamento de malignidades celulares em terapia celular adotiva |
| SG11202105502RA (en) | 2018-11-30 | 2021-06-29 | Juno Therapeutics Inc | Methods for treatment using adoptive cell therapy |
| SG11202106053SA (en) * | 2018-12-07 | 2021-07-29 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for immunotherapy |
| CA3123314A1 (fr) | 2018-12-21 | 2020-06-25 | Octane Biotech Inc. | Carrousel pour unites de production biologique modulaires |
| CN113195725A (zh) | 2018-12-21 | 2021-07-30 | 隆萨沃克斯维尔股份有限公司 | 病毒载体的自动化生产 |
| EP3914690A4 (fr) | 2019-02-08 | 2022-11-09 | Lonza Walkersville, Inc. | Méthodes et dispositifs de concentration cellulaire destinés à être utilisés dans des bioréacteurs automatisés |
| WO2020180882A1 (fr) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Récepteurs d'antigènes chimériques anti-cd19 et leurs utilisations en immunothérapie |
| JPWO2020196412A1 (fr) * | 2019-03-26 | 2020-10-01 | ||
| BR112021024404A2 (pt) | 2019-06-07 | 2022-04-19 | Juno Therapeutics Inc | Cultura de célula t automatizada |
| US20220306993A1 (en) * | 2019-06-10 | 2022-09-29 | I Peace, Inc. | Erythrocyte removal device, mononuclear cell collector, cell culture device, cell culture system, cell culture method, and mononuclear cell collection method |
| SG11202113356XA (en) | 2019-06-12 | 2021-12-30 | Juno Therapeutics Inc | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| KR20220073738A (ko) | 2019-08-30 | 2022-06-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 분류를 위한 기계 학습 방법 |
| AU2020369940A1 (en) | 2019-10-21 | 2022-05-26 | Flaskworks, Llc | Systems and methods for cell culturing |
| AU2020377043A1 (en) | 2019-10-30 | 2022-06-02 | Juno Therapeutics Gmbh | Cell selection and/or stimulation devices and methods of use |
| KR20220131892A (ko) | 2019-11-05 | 2022-09-29 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료용 ｔ 세포 조성물의 속성 결정 방법 |
| JP2023504736A (ja) | 2019-12-06 | 2023-02-06 | ジュノー セラピューティクス インコーポレイテッド | Ｇｐｒｃ５ｄ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法 |
| JP2023504740A (ja) | 2019-12-06 | 2023-02-06 | ジュノー セラピューティクス インコーポレイテッド | Ｂｃｍａ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法 |
| BR112022010310A2 (pt) | 2019-12-06 | 2022-08-16 | Juno Therapeutics Inc | Métodos relacionados com a toxicidade e resposta associada com terapia celular para tratamento de malignidades de célula b |
| US20240182920A1 (en) * | 2020-01-22 | 2024-06-06 | Carsgen Therapeutics Co., Ltd. | Method for transducing cells with viral vector |
| CN115315269A (zh) | 2020-01-24 | 2022-11-08 | 朱诺治疗学股份有限公司 | 在过继细胞疗法中给药和治疗滤泡性淋巴瘤和边缘区淋巴瘤的方法 |
| CN115427550A (zh) | 2020-01-28 | 2022-12-02 | 朱诺治疗学股份有限公司 | T细胞转导方法 |
| IL294956A (en) * | 2020-02-06 | 2022-09-01 | Cutiss Ag | Apparatus and method for isolating cells |
| AU2021219764A1 (en) | 2020-02-12 | 2022-09-01 | Juno Therapeutics, Inc. | BCMA-directed chimeric antigen receptor T cell compositions and methods and uses thereof |
| US20230190798A1 (en) | 2020-02-12 | 2023-06-22 | Juno Therapeutics, Inc. | Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof |
| CN115885036A (zh) * | 2020-04-03 | 2023-03-31 | 米伦纽姆医药公司 | 提高的病毒转导效率 |
| WO2021207689A2 (fr) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Méthodes et utilisations associées à une thérapie cellulaire modifiée à l'aide d'un récepteur antigénique chimérique ciblant un antigène de maturation des lymphocytes b |
| CN115803824A (zh) | 2020-05-13 | 2023-03-14 | 朱诺治疗学股份有限公司 | 鉴定与临床反应相关的特征的方法及其用途 |
| EP4150057A2 (fr) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Procédé de production de lots de cellules donneuses exprimant un récepteur recombinant |
| KR20230095918A (ko) | 2020-08-05 | 2023-06-29 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법 |
| WO2022133030A1 (fr) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Polythérapie de thérapie cellulaire et d'inhibiteur de bcl2 |
| KR20230137402A (ko) | 2021-02-20 | 2023-10-04 | 카이트 파마 인코포레이티드 | 면역요법 선택을 위한 유전자 마커 |
| US20240168012A1 (en) | 2021-03-22 | 2024-05-23 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
| CN117321200A (zh) | 2021-03-22 | 2023-12-29 | 朱诺治疗学股份有限公司 | 评估病毒载体颗粒效力的方法 |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| WO2022234009A2 (fr) | 2021-05-06 | 2022-11-10 | Juno Therapeutics Gmbh | Méthodes de stimulation et de transduction de lymphocytes t |
| KR20230173179A (ko) | 2021-05-14 | 2023-12-26 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t세포 요법 |
| CN118742810A (zh) | 2022-02-15 | 2024-10-01 | 凯德药业股份有限公司 | 从免疫疗法预测不良事件 |
| WO2023225569A1 (fr) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Fabrication de particules virales |
| WO2023230548A1 (fr) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Procédé de prédiction d'une réponse à une thérapie par lymphocyte t |
| WO2023230581A1 (fr) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Procédés de fabrication de thérapies par lymphocytes t |
| WO2023250400A1 (fr) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Méthodes de traitement pour thérapie de deuxième ligne par cellules car-t ciblées par cd19 |
| WO2024097992A2 (fr) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particules présentant des fusions de molécules d'adhésion |
| WO2024098038A2 (fr) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Construction polynucléotidique et vecteurs viraux et procédés associés |
| WO2024124132A1 (fr) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Procédés d'apprentissage automatique pour prédire un phénotype cellulaire au moyen d'une imagerie holographique |
| WO2024145732A1 (fr) * | 2023-01-03 | 2024-07-11 | 深圳华大生命科学研究院 | Système fluidique de triage et dispositif connexe, procédé de triage fluidique, et procédé de triage cellulaire |
| US20240285762A1 (en) | 2023-02-28 | 2024-08-29 | Juno Therapeutics, Inc. | Cell therapy for treating systemic autoimmune diseases |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4163519A (en) | 1977-11-01 | 1979-08-07 | Union Carbide Corporation | Compensating rotor |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (fr) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| SE454413B (sv) | 1986-09-12 | 1988-05-02 | Alfa Laval Separation Ab | Centrifugalseparator med en rotor, vari ett bojligt organ strecker sig ett stycke lengs rotorns omkrets |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| WO1990007380A2 (fr) | 1988-12-28 | 1990-07-12 | Stefan Miltenyi | Procedes et matieres pour la separation magnetique a gradient eleve de matieres biologiques |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| EP0557459B1 (fr) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Genes de fusion selectionnables bifonctionnels |
| US5911983A (en) * | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| EP0804590A1 (fr) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd) |
| US5437998A (en) * | 1993-09-09 | 1995-08-01 | Synthecon, Inc. | Gas permeable bioreactor and method of use |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| CA2238434A1 (fr) | 1995-12-15 | 1997-06-19 | Systemix, Inc. | Procede visant a obtenir un surnageant vectoriel retroviral a haute efficacite de transduction |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| ATE186235T1 (de) | 1996-04-24 | 1999-11-15 | Claude Fell | Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut |
| EP0995802B1 (fr) * | 1998-07-10 | 2009-12-23 | Universite Pierre Et Marie Curie | Procédé pour l'apport des acides nucléiques dans les cellules in vitro ou ex vivo |
| EP1109921A4 (fr) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| AU1675600A (en) | 1998-12-24 | 2000-07-31 | Biosafe S.A. | Blood separation system particularly for concentrating hematopoietic stem cells |
| US20030119185A1 (en) * | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| US20020131960A1 (en) | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| AU2001297703B2 (en) | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| DE10136375A1 (de) | 2001-07-26 | 2003-02-13 | Cellgenix Technologie Transfer | Verfahren zur Anreicherung von Zellen |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US7001513B2 (en) | 2003-08-06 | 2006-02-21 | Nuvue Technologies, Inc. | Automated processing of a biological component |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| CN101146559B (zh) | 2005-03-23 | 2012-09-05 | 生物安全股份有限公司 | 用于再生医学的收集、处理和移植包括成人干细胞的细胞亚群的集成系统 |
| JP5453629B2 (ja) * | 2006-08-23 | 2014-03-26 | タカラバイオ株式会社 | 遠心用袋状容器を使用した遺伝子導入方法 |
| CA2682527C (fr) | 2007-03-30 | 2017-07-11 | Memorial Sloan-Kettering Cancer Center | Expression constitutive de ligands costimulants sur des lymphocytes t transferes de maniere adoptive |
| EP3338895B1 (fr) | 2007-12-07 | 2022-08-10 | Miltenyi Biotec B.V. & Co. KG | Systèmes et procédés de traitement d'échantillons |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| JP5746025B2 (ja) * | 2008-07-16 | 2015-07-08 | ケーセップ・システムズ，リミテッド・ライアビリティ・カンパニー | 流動床を使用して粒子を操作するための方法及びシステム |
| SI2496698T1 (sl) | 2009-11-03 | 2019-07-31 | City Of Hope | Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic |
| WO2011116221A1 (fr) | 2010-03-18 | 2011-09-22 | Synergenesis, Inc. | Système permettant de purifier certaines populations cellulaires dans le sang ou la moelle osseuse par déplétion d'autres populations cellulaires |
| SE535275C2 (sv) | 2010-03-31 | 2012-06-12 | Alfa Laval Corp Ab | Centrifugalseparator och rotor |
| CN103002932B (zh) * | 2010-07-15 | 2015-04-22 | 泰尔茂比司特公司 | 在用于生物流体的离心装置中优化旋转时间的方法 |
| SG190997A1 (en) | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG192010A1 (en) * | 2011-01-18 | 2013-08-30 | Univ Pennsylvania | Compositions and methods for treating cancer |
| CN106074601A (zh) | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| EP2714886B1 (fr) * | 2011-05-30 | 2020-01-22 | Atech Partners Ltd. | Système de bioréacteur pour la culture continue de cellules |
| CN102329776B (zh) * | 2011-07-20 | 2013-02-27 | 华中农业大学 | 一种表达Nectin-1基因胞外区片段的PK-15细胞系及其构建方法 |
| WO2013051718A1 (fr) * | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | Récepteur d'antigène chimérique |
| US10208086B2 (en) | 2011-11-11 | 2019-02-19 | Fred Hutchinson Cancer Research Center | Cyclin A1-targeted T-cell immunotherapy for cancer |
| EP2594632A1 (fr) * | 2011-11-18 | 2013-05-22 | Miltenyi Biotec GmbH | Procédé et dispositif de modification cellulaire |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (fr) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation |
| EP2817625A2 (fr) * | 2012-02-23 | 2014-12-31 | Stage Cell Therapeutics GmbH | Isolement chromatographique des cellules et d'autres materiaux biologiques complexes |
| EP2820138B1 (fr) | 2012-02-29 | 2020-10-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Transduction rétrovirale utilisant des poloxamères |
| SG11201405185PA (en) | 2012-03-13 | 2014-10-30 | Emd Millipore Corp | Use of centrifugation-aided infection to increase virus titer |
| US9751928B2 (en) | 2012-05-03 | 2017-09-05 | Fred Hutchinson Cancer Research Center | Enhanced affinity T cell receptors and methods for making the same |
| EP2855666B1 (fr) * | 2012-05-25 | 2019-12-04 | Cellectis | Utilisation de pré-t alpha ou d'un variant fonctionnel de celui-ci pour expanser des lymphocytes t déficients en tcr-alpha |
| EP2698208A1 (fr) | 2012-08-14 | 2014-02-19 | Fresenius Kabi Deutschland GmbH | Dispositif de centrifugation et procédé de fonctionnement dýun dispositif de centrifugation |
| RU2700765C2 (ru) | 2012-08-20 | 2019-09-19 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ и композиции для клеточной иммунотерапии |
| WO2014055668A1 (fr) | 2012-10-02 | 2014-04-10 | Memorial Sloan-Kettering Cancer Center | Compositions et procédés d'immunothérapie |
| WO2014097442A1 (fr) | 2012-12-20 | 2014-06-26 | 三菱電機株式会社 | Dispositif embarqué et programme |
| EP3241897B1 (fr) * | 2013-03-07 | 2018-10-03 | Baylor College of Medicine | Ciblage cd138 dans le domaine du cancer |
| TWI654206B (zh) * | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| ES2831315T3 (es) * | 2013-04-03 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | Generación efectiva de células T dirigidas al tumor derivadas de células madre pluripotentes |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| BR112016009898A2 (pt) | 2013-10-31 | 2017-12-05 | Hutchinson Fred Cancer Res | células-tronco/progenitoras hematopoiéticas e efetoras não-t modificadas e usos das mesmas |
| KR20220136455A (ko) | 2014-04-23 | 2022-10-07 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 치료용 면역 세포 집단의 단리, 배양 및 유전자 조작 방법 |
| US10131876B2 (en) | 2014-04-24 | 2018-11-20 | Miltenyi Biotec Gmbh | Method for automated generation of genetically modified T cells |
| PT3757206T (pt) | 2014-11-05 | 2024-05-21 | Juno Therapeutics Inc | Métodos de transdução e processamento de células |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
-
2015
- 2015-11-04 PT PT201760477T patent/PT3757206T/pt unknown
- 2015-11-04 EP EP24168832.4A patent/EP4407036A3/fr active Pending
- 2015-11-04 CN CN201580072404.4A patent/CN107109438B/zh active Active
- 2015-11-04 PT PT158022319T patent/PT3215601T/pt unknown
- 2015-11-04 ES ES15802231T patent/ES2805674T3/es active Active
- 2015-11-04 WO PCT/US2015/059030 patent/WO2016073602A2/fr active Application Filing
- 2015-11-04 RS RS20200887A patent/RS60685B1/sr unknown
- 2015-11-04 LT LTEP15802231.9T patent/LT3215601T/lt unknown
- 2015-11-04 KR KR1020177015404A patent/KR102635942B1/ko active IP Right Grant
- 2015-11-04 IL IL292450A patent/IL292450A/en unknown
- 2015-11-04 TW TW110125506A patent/TWI787903B/zh active
- 2015-11-04 KR KR1020247004412A patent/KR20240023204A/ko active Application Filing
- 2015-11-04 AU AU2015343121A patent/AU2015343121B2/en active Active
- 2015-11-04 TW TW104136385A patent/TWI735418B/zh active
- 2015-11-04 SI SI201531268T patent/SI3215601T1/sl unknown
- 2015-11-04 PL PL15802231T patent/PL3215601T3/pl unknown
- 2015-11-04 SG SG10202002324SA patent/SG10202002324SA/en unknown
- 2015-11-04 MA MA040318A patent/MA40318A/fr unknown
- 2015-11-04 SG SG11201703656PA patent/SG11201703656PA/en unknown
- 2015-11-04 TW TW111132488A patent/TW202315948A/zh unknown
- 2015-11-04 EP EP15802231.9A patent/EP3215601B1/fr active Active
- 2015-11-04 PL PL20176047.7T patent/PL3757206T3/pl unknown
- 2015-11-04 MY MYPI2017000656A patent/MY186199A/en unknown
- 2015-11-04 NZ NZ769598A patent/NZ769598A/en unknown
- 2015-11-04 IL IL252126A patent/IL252126B/en unknown
- 2015-11-04 HU HUE15802231A patent/HUE050264T2/hu unknown
- 2015-11-04 NZ NZ769595A patent/NZ769595A/en unknown
- 2015-11-04 BR BR112017009220-4A patent/BR112017009220B1/pt active IP Right Grant
- 2015-11-04 CN CN202111026157.8A patent/CN113736828A/zh active Pending
- 2015-11-04 DK DK15802231.9T patent/DK3215601T3/da active
- 2015-11-04 EP EP20176047.7A patent/EP3757206B1/fr active Active
- 2015-11-04 DK DK20176047.7T patent/DK3757206T3/da active
- 2015-11-04 CA CA2966538A patent/CA2966538A1/fr not_active Abandoned
- 2015-11-04 FI FIEP20176047.7T patent/FI3757206T3/fi not_active Application Discontinuation
- 2015-11-04 BR BR122020002722-3A patent/BR122020002722B1/pt not_active IP Right Cessation
- 2015-11-04 MX MX2017005823A patent/MX2017005823A/es unknown
- 2015-11-04 JP JP2017543300A patent/JP6740234B2/ja active Active
- 2015-11-04 US US14/932,660 patent/US10428351B2/en active Active
-
2017
- 2017-05-03 MX MX2022000159A patent/MX2022000159A/es unknown
- 2017-05-03 MX MX2021001334A patent/MX2021001334A/es unknown
- 2017-05-04 PH PH12017500824A patent/PH12017500824A1/en unknown
-
2019
- 2019-08-14 US US16/541,083 patent/US11802295B2/en active Active
-
2020
- 2020-07-17 HR HRP20201128TT patent/HRP20201128T1/hr unknown
- 2020-07-22 JP JP2020124934A patent/JP7202332B2/ja active Active
- 2020-08-13 CY CY20201100763T patent/CY1123254T1/el unknown
- 2020-09-14 AU AU2020233623A patent/AU2020233623B2/en active Active
-
2022
- 2022-11-03 AU AU2022263539A patent/AU2022263539A1/en active Pending
- 2022-12-23 JP JP2022206247A patent/JP2023024691A/ja active Pending
-
2023
- 2023-09-21 US US18/371,302 patent/US20240011051A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40318A (fr) | Procédés de transduction et de traitement de cellules | |
| WO2020123301A3 (fr) | Génération de réseaux spatiaux avec des gradients | |
| WO2017139505A3 (fr) | Procédés et compositions pour modifier un gène mutant de la dystrophine dans le génome d'une cellule | |
| MX2019001276A (es) | Viriones de virus adenoasociados con cápside variante y métodos para su uso. | |
| BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
| MX2020009648A (es) | Muestreador de lecho fijo y metodos relacionados. | |
| WO2018119057A3 (fr) | Réseau comprenant une amorce de séquençage et une entité non de séquençage | |
| Li et al. | Chemical constituents and biological activities of plants from the genus Rubus | |
| WO2018183848A8 (fr) | Milieu de culture de micro-organismes et compositions et procédés associés | |
| BR112019008774A2 (pt) | método de preparação de extrato de cereal | |
| EA202192893A1 (ru) | Среда для культивирования эукариотических клеток | |
| EA201892117A1 (ru) | Неразрушающее генотипирование семян | |
| WO2016051177A3 (fr) | Procédés et kits | |
| FR3032448B1 (fr) | Enrichissement et culture selective de mycobacteries | |
| ES2545829A1 (es) | Concentración de cultivos de microalgas por un proceso de eliminación osmótica del medio utilizando disoluciones de glicerol | |
| BR112017004002A2 (pt) | multicâmara com motocompressores ou motobombas de ultra-alta pressão ou hidráulicas para comprimir gás ou líquido a ultra-alta pressão, formada por várias cãmaras de diferente tamanho de modo concêntricas, onde cada câmara contém no interior câmaras menores | |
| WO2016037036A3 (fr) | Procédés de détection d'oligomères bêta-amyloïdes | |
| RU2015111463A (ru) | Способ возделывания чечевицы тарелочной в смешанном посеве | |
| RU2015147257A (ru) | Устройство для выделения клеточных фракций из тканей человека и животных и способ его применения | |
| LANLAN | The Xujiahui Legacy | |
| Phuong et al. | MECHANICAL STRETCH ALTERS THE EXPRESSION PROFILE OF MECHANOSENSITIVE CHANNELS IN MOUSE RETINAL GANGLION CELLS VIA ACTIVATION OF TRPV4 | |
| Zhivaga | INFLUENCE OF ULTRASOUND PLASTIC DEFORMATION ON WEAR RESISTANCE OF SURFACES OF DETAILS | |
| RU2014100735A (ru) | Способ подвидовой дифференциации штаммов возбудителя чумы методом полимеразной цепной реакции | |
| CN106687603A8 (zh) | 用于果皮基因分型的体系和方法 | |
| HATTORI et al. | Detection of zoospores of the red rot disease fungus Pythium porphyrae by PCR in seawater from Porphyra cultivation farms at aichi prefecture in 2004 and 2005 |